Hyundai Pharmaceutical Co. Ltd. filed for marketing approval with the Ministry of Food and Drug Safety in South Korea for Acerus Pharmaceuticals Corp.'s Natesto, a testosterone deficiency drug.

The company had acquired an exclusive license to market Natesto in South Korea from Acerus in December 2016.

If approved, Natesto will be the first and only testosterone nasal gel indicated for the treatment of low testosterone in South Korea.